RT Journal Article
T1 Epidemiology of Intracranial Hemorrhage Associated with Oral Anticoagulants in Spain: Trends in Anticoagulation Complications Registry - The TAC 2 Study.
A1 Zapata-Wainberg, Gustavo
A1 Quintas, Sonia
A1 Ximénez-Carrillo Rico, Álvaro
A1 Masjuán Vallejo, Jaime
A1 Cardona, Pere
A1 Castellanos Rodrigo, Mar
A1 Benavente Fernández, Lorena
A1 García Pastor, Andrés
A1 Egido, José
A1 Maciñeiras, José
A1 Serena, Joaquín
A1 Freijo Guerrero, María Del Mar
A1 Moniche, Francisco
A1 Vivancos, José
K1 Direct oral anticoagulants
K1 Incidence
K1 Intracranial hemorrhage
K1 Neuroepidemiology
K1 Oral anticoagulants
K1 Vitamin K antagonists
AB Patients receiving treatment with oral anticoagulants (OACs) are at risk of intracranial hemorrhage (ICH). In this study, we describe the epidemiological and clinical characteristics of patients receiving OACs who experience ICH and compare those receiving vitamin K antagonists (ICH-VKAs) with those receiving direct OACs (ICH-DOACs). We performed a national, multicenter, descriptive, observational, retrospective study of all adult patients receiving OACs who were admitted to the neurology department with ICH over a 1-year period. The study population was divided into 2 groups (ICH-VKAs and ICH-DOACs). Epidemiological, clinical, radiological, and therapy-related variables, as well as functional outcome, were compared at 3 months. A total of 366 cases were included (331 ICH-VKAs, 35 ICH- DOACs). The crude annual incidence of OAC-induced ICH was 3.8 (95% CI, 2.78-3.41) per 100,000 inhabitants/year. The mean (± SD) age was greater for ICH-DOACs (81.5 ± 8.3 vs. 77.7 ± 8.3 years; p = 0.012). The median (IQR) volume of the hemorrhage was lower for ICH-DOACs (11 [30.8] vs. 25 [50.7] mL; p = 0.03). The functional independence rate at 3 months (modified Rankin Scale, mRS  We found that the incidence of OAC-induced ICH was greater than in previous studies. Hemorrhage volume and mortality were lower in ICH-DOACs than in ICH-VKAs. After stroke, DOACs were the most frequently indicated antithrombotic treatment.
SN 1664-9737
YR 2018
FD 2018-04-04
LK https://hdl.handle.net/10668/25049
UL https://hdl.handle.net/10668/25049
LA en
DS RISalud
RD Apr 12, 2025